Effectiveness of P-aminobenzyol-O-phenylenediamine (Goe 1734) against mouse, rat, and human tumour cells
- 1 May 1985
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 15 (1) , 88-90
- https://doi.org/10.1007/bf00257303
Abstract
The new N-phenylbenzamide derivative Goe 1734 was tested for its antitumour effects against mouse, rat, and human tumours. The preparation showed marginal activity against leukaemia L1210, moderate activity against Lewis lung carcinoma, and high activity against osteosarcoma C22LR and Brown Norway myeloid leukaemia. In the subrenal capsule assay the drug was active against four (cisplatin: 2) of nine human tumours. An in vitro clonogenic assay did not reveal any activity of Goe 1734 when mouse osteosarcoma or human tumour cells were exposed for only 1 h. However, continuous exposure led to 70% or greater inhibition of colony formation at concentrations of 0.1–1 μg/ml (osteosarcoma) or 0.2–2 μg/ml (human tumours).Keywords
This publication has 5 references indexed in Scilit:
- Improvements and limitations of the subrenal capsule assay for determining tumour sensitivity to cytostatic drugsEuropean Journal of Cancer and Clinical Oncology, 1984
- Inhibitors of Poly(Adenosine Diphosphate-Ribose) Synthesis: Effect on Other Metabolic ProcessesScience, 1984
- Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: Six-day subrenal capsule assayCancer, 1981
- Primary Bioassay of Human Tumor Stem CellsScience, 1977
- A cell dispersion technique for use in quantitative transplantation studies with solid tumoursEuropean Journal of Cancer (1965), 1965